Credit Suisse Group reissued their outperform rating on shares of Shire PLC (LON:SHP) in a research note published on Monday. The firm currently has a GBX 4,500 ($59.38) price target on the biopharmaceutical company’s stock.
SHP has been the subject of a number of other research reports. Royal Bank Of Canada reiterated an outperform rating on shares of Shire PLC in a research note on Friday, July 7th. HSBC Holdings plc upgraded Shire PLC to a hold rating and set a GBX 4,450 ($58.72) price objective for the company in a research note on Thursday, July 6th. J P Morgan Chase & Co reiterated an overweight rating and set a GBX 6,000 ($79.18) price objective on shares of Shire PLC in a research note on Tuesday, July 11th. Barclays PLC reiterated an equal weight rating and set a GBX 4,000 ($52.78) price objective on shares of Shire PLC in a research note on Monday. Finally, Shore Capital reiterated a buy rating on shares of Shire PLC in a research note on Wednesday, September 20th. Four analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Shire PLC currently has an average rating of Buy and an average price target of GBX 5,571.33 ($73.52).
Shire PLC (LON:SHP) traded up 0.72% during mid-day trading on Monday, reaching GBX 3721.00. The company had a trading volume of 4,132,431 shares. The stock’s 50-day moving average price is GBX 3,811.88 and its 200 day moving average price is GBX 4,172.02. Shire PLC has a 52 week low of GBX 3,435.50 and a 52 week high of GBX 5,186.00. The firm’s market capitalization is GBX 33.73 billion.
ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/10/31/shire-plc-shp-receives-outperform-rating-from-credit-suisse-group.html.
The company also recently declared a dividend, which was paid on Friday, October 20th. Shareholders of record on Thursday, September 7th were paid a dividend of GBX 3.85 ($0.05) per share. This represents a yield of 0.1%. The ex-dividend date was Thursday, September 7th.
In related news, insider Flemming Ornskov acquired 8,400 shares of the business’s stock in a transaction dated Tuesday, August 22nd. The shares were acquired at an average price of GBX 3,665 ($48.36) per share, with a total value of £307,860 ($406,254.95). Also, insider Anne Minto acquired 190 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were bought at an average cost of GBX 3,785 ($49.95) per share, for a total transaction of £7,191.50 ($9,489.97).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.